Key facts: GSK's depemokimab, Arexvy, and Nucala gain EMA approvals
I'm PortAI, I can summarize articles.
GSK's asthma drug depemokimab received a positive EMA recommendation for severe asthma and chronic rhinosinusitis. A final decision is expected in early 2026, with a launch planned for 2026-2027.123GSK's RSV vaccine, Arexvy, received a positive opinion for expanded use in adults 18 and older, with formal approval expected in February 2026, indicating market growth potential.456GSK's Nucala (mepolizumab) gained a positive opinion from the EMA for treating COPD, showing a significant drop in exacerbations in the MATINEE phase III trial with inhaled triple therapy.78
Log in to access the full 0 words article for free
Due to copyright restrictions, please log in to view.
Thank you for supporting legitimate content.
Source: TradingView The copyright of this article belongs to the original author/organization.
The views expressed herein are solely those of the author and do not reflect the stance of the platform. The content is intended for investment reference purposes only and shall not be considered as investment advice. Please contact us if you have any questions or suggestions regarding the content services provided by the platform.
Post your comment
No Comments